Epizyme (EPZM) Downgraded to “Market Perform” at Leerink Swann

Leerink Swann cut shares of Epizyme (NASDAQ:EPZM) from an outperform rating to a market perform rating in a report released on Tuesday, Marketbeat Ratings reports. They currently have $24.00 price objective on the biopharmaceutical company’s stock. Leerink Swann also issued estimates for Epizyme’s FY2019 earnings at ($2.86) EPS, FY2020 earnings at ($2.11) EPS, FY2021 earnings at ($1.44) EPS and FY2022 earnings at ($0.14) EPS.

A number of other research analysts have also recently issued reports on the company. ValuEngine cut Epizyme from a hold rating to a sell rating in a research note on Thursday, June 28th. HC Wainwright restated a buy rating and issued a $25.00 price target on shares of Epizyme in a research note on Wednesday, June 27th. BidaskClub cut Epizyme from a hold rating to a sell rating in a research note on Wednesday, June 20th. Wedbush boosted their price target on Epizyme from $20.00 to $25.00 in a research note on Friday, May 18th. Finally, Roth Capital set a $24.00 price target on Epizyme and gave the stock a buy rating in a research note on Tuesday, April 24th. Two research analysts have rated the stock with a sell rating, four have given a hold rating and seven have given a buy rating to the company’s stock. The company has a consensus rating of Hold and a consensus price target of $23.00.

Shares of Epizyme opened at $12.40 on Tuesday, Marketbeat Ratings reports. The firm has a market cap of $877.28 million, a price-to-earnings ratio of -5.69 and a beta of 2.24. Epizyme has a 12-month low of $11.15 and a 12-month high of $21.40.

Epizyme (NASDAQ:EPZM) last announced its quarterly earnings data on Tuesday, May 8th. The biopharmaceutical company reported ($0.49) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.54) by $0.05. During the same period in the previous year, the firm posted ($0.56) EPS. equities research analysts forecast that Epizyme will post -2.22 EPS for the current fiscal year.

Several hedge funds have recently bought and sold shares of the company. Schwab Charles Investment Management Inc. increased its position in Epizyme by 13.2% during the fourth quarter. Schwab Charles Investment Management Inc. now owns 245,756 shares of the biopharmaceutical company’s stock valued at $3,085,000 after acquiring an additional 28,588 shares during the last quarter. Teacher Retirement System of Texas purchased a new stake in Epizyme during the fourth quarter valued at $202,000. The Manufacturers Life Insurance Company increased its position in Epizyme by 18.5% during the fourth quarter. The Manufacturers Life Insurance Company now owns 38,451 shares of the biopharmaceutical company’s stock valued at $482,000 after acquiring an additional 6,005 shares during the last quarter. Bank of New York Mellon Corp increased its position in Epizyme by 5.3% during the fourth quarter. Bank of New York Mellon Corp now owns 212,983 shares of the biopharmaceutical company’s stock valued at $2,672,000 after acquiring an additional 10,805 shares during the last quarter. Finally, BlackRock Inc. increased its position in Epizyme by 17.1% during the fourth quarter. BlackRock Inc. now owns 3,965,391 shares of the biopharmaceutical company’s stock valued at $49,766,000 after acquiring an additional 579,662 shares during the last quarter. Hedge funds and other institutional investors own 85.22% of the company’s stock.

Epizyme Company Profile

Epizyme, Inc, a clinical stage biopharmaceutical company, discovers and develops novel epigenetic medicines for patients with cancer and other diseases in the United States. Its product candidates include tazemetostat, an inhibitor of the EZH2, which is in Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma (NHL); Phase II clinical trial for relapsed or refractory patients with mesothelioma; Phase I dose-escalation and expansion study for children with INI1-negative solid tumors; Phase II clinical trials for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL); Phase Ib/II clinical trial in elderly patients with DLBCL; and Phase II clinical trial for relapsed or refractory patients with mesothelioma characterized by BAP1 loss-of-function,; and Phase Ib/II clinical trial for the treatment of patients with relapsed or refractory metastatic non-small cell lung cancer, as well as Phase II clinical trial in adult patients with ovarian cancer.

Analyst Recommendations for Epizyme (NASDAQ:EPZM)

Receive News & Ratings for Epizyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply